Today: 18 May 2026
T-Mobile stock price: TMUS closes higher as $3 billion debt redemption looms
24 January 2026
1 min read

T-Mobile stock price: TMUS closes higher as $3 billion debt redemption looms

NEW YORK, Jan 24, 2026, 16:35 EST — The market has closed for the day.

  • T-Mobile shares closed Friday at $186.03, edging up roughly 0.3%.
  • The company announced plans to redeem $3 billion of its 4.75% senior notes maturing in 2028, effective Feb. 1.
  • Investors have their sights set on T-Mobile’s earnings report and capital markets update scheduled for Feb. 11.

T-Mobile US, Inc. shares ended Friday’s session 0.3% higher at $186.03. The stock fluctuated between $184.06 and $186.92 as U.S. markets closed for the weekend, with trading scheduled to pick up again on Monday.

The modest shift carries weight as investors revisit telecom balance sheets, where leverage and borrowing costs can swiftly shift sentiment amid rate changes. For T-Mobile, a new debt repayment plan refocuses attention on cash deployment.

The announcement comes just before the company’s major upcoming event, where management will discuss fourth-quarter results and outline priorities for 2026. Timing here matters, even if the news itself is standard.

Late Thursday, T-Mobile announced that its wholly-owned unit, T-Mobile USA, will redeem the entire $3 billion principal on its 4.750% senior notes due 2028. The amount breaks down evenly: $1.5 billion held publicly and another $1.5 billion owned by Deutsche Telekom. The redemption price is set at 100% of principal plus any accrued and unpaid interest, with payments processed through The Depository Trust Company.

A redemption means a company is paying off its corporate debt ahead of schedule. Investors usually take it as a signal that the firm has enough cash to reduce its borrowings. But it can also prompt questions about what other opportunities that money might have missed out on.

T-Mobile’s shift happens in a sector where investors focus on cash flow, customer churn, and promotional pressure, with Verizon and AT&T as the nearest publicly traded rivals. Signs of ramped-up competition usually surface first in their guidance.

Near-term, the bigger risk might be capital allocation overshadowing operations. Should investors suspect the company is front-loading cash to handle maturities—or if management’s February outlook disappoints—the stock could lose its gains fast.

T-Mobile’s next big date is Feb. 11, when it will hold its Q4 2025 earnings call along with a capital markets day update, starting at 8:30 a.m. ET.

Traders will be eyeing Monday’s open for signs of follow-through from Friday’s close. Attention will then shift to the Feb. 1 note redemption date to see if more details emerge about how T-Mobile plans to fund the payoff.

Latest articles

Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

18 May 2026
Quince Therapeutics was last quoted at $1.15 before Monday’s Nasdaq open after Nantahala Capital Management disclosed 7.52% beneficial ownership. The company’s latest filing reported no current product candidates and raised substantial doubt about its ability to continue as a going concern. Quince is seeking shareholder approval for another reverse stock split at its June 11 meeting. The company remains out of compliance with Nasdaq’s $50 million market value rule.
Macy’s Gains Pre-Market as Berkshire Buys In — What’s Ahead for Traders

Macy’s Gains Pre-Market as Berkshire Buys In — What’s Ahead for Traders

18 May 2026
Macy’s shares rose in premarket trading after Berkshire Hathaway disclosed a new stake of 3.04 million shares, valued at about $55 million as of March 31. The stock closed Friday at $18.41 and last traded at $18.99 premarket with 128,170 shares exchanged. Macy’s will report first-quarter results on June 3. Tariffs, fuel costs, and weak discretionary spending remain risks for the retailer.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

18 May 2026
ImmunityBio said Monday five U.S. patents protect its Anktiva-plus-BCG bladder cancer treatment through at least 2035, following an exclusive U.S. supply deal with Japan BCG Laboratory. The company plans to seek FDA approval for the Tokyo-172 BCG strain, which is not yet approved in the U.S. ImmunityBio shares last traded at $7.97 before the Nasdaq open.
Why Virax Biolabs Stock Is Jumping Before the Bell Today

Why Virax Biolabs Stock Is Jumping Before the Bell Today

18 May 2026
Virax Biolabs shares jumped in pre-market trading Monday, indicated at $0.3458 after closing Friday at $0.1535. The move followed a sponsored TV segment featuring CEO James Foster and a new SEC filing showing Armistice Capital holds 4.99% of shares. ViraxImmune, the company’s main test, remains in development and is not approved for diagnostic use. No new company press release appeared over the weekend.

Popular

Nokia’s AI stock rally set for Monday showdown after turbulent holiday week

Nokia’s AI stock rally set for Monday showdown after turbulent holiday week

17 May 2026
Nokia shares closed Friday at 11.905 euros in Helsinki, up 8.8% from May 8 after a four-day trading week. The stock’s rally follows strong first-quarter results, with AI and cloud sales up 49% and a raised 2026 growth target. Nokia named Emma Falck as Mobile Infrastructure president, effective September 1. The OMX Helsinki 25 ended Friday at 6,272.91, up 0.5% from the previous week.
Goldman Sachs stock slides into Fed week after CEO pay disclosure
Previous Story

Goldman Sachs stock slides into Fed week after CEO pay disclosure

Compass Group share price hits 52-week low; investors eye Feb. 5 update and dividend date
Next Story

Compass Group share price hits 52-week low; investors eye Feb. 5 update and dividend date

Go toTop